NAPSR News: FDA Advisory Committee recommends approval of Novartis’ psoriasis treatment

The Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) to the US Food and Drug Administration (FDA) made a unanimous decision to support the approval of Novartis’ investigational selective interleukin-17A (IL-17A) inhibitor, AIN457...



via Marketing - Latest News http://ift.tt/1s48eBo